MetaCap

Annovis Bio (ANVS) vs RenovoRx (RNXT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

RenovoRx (RNXT) has outperformed Annovis Bio (ANVS) over the past year, gaining 18.3% versus a loss of 81.2%. Over five years, RNXT leads with a -85.3% price change compared with -97.2% for ANVS. RenovoRx is the larger company by market cap ($45.5 million vs $44.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANVS-81.23%RNXT+18.34%
+232%+67%-97%
Nov 21, 20251 yearNov 20, 2026
ANVS-97.38%RNXT-85.71%
+5%-49%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANVS versus RNXT key metrics
MetricANVSRNXT
Share price$0.7113$0.942
Market cap$44.12M$45.45M
1-day change-4.96%-10.29%
YTD return-79.44%+12.14%
1-year return-81.23%+18.34%
5-year return-97.24%-85.26%
EPS (TTM)$-1.55$-0.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$1.12M
Revenue growth (YoY)—+2511.63%
Net income (latest FY)$-28.85M$-11.17M
Gross margin—70.88%
Operating margin—-1113.98%
Net margin—-994.48%
52-week high$5.50$2.59
52-week low$0.62$0.77
Distance from 52-week high-87.07%-63.63%
Analyst consensusnonenone
Avg. price target upside+1376.17%+656.90%
Average volume1.82M815.75K
Shares outstanding62.02M48.25M
Employees717
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RNXT has outperformed ANVS by 99.6 percentage points over the past year.

About Annovis Bio

ANVS stock →

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About RenovoRx

RNXT stock →

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

ANVS vs RNXT FAQ

Which is bigger, Annovis Bio or RenovoRx?

RenovoRx (RNXT) is larger, with a market capitalization of $45.45M compared with $44.12M for Annovis Bio (ANVS).

Which stock has performed better over the past year, ANVS or RNXT?

RNXT returned +18.34% over the past 12 months, compared with -81.23% for ANVS (price return, excluding dividends). Past performance does not predict future results.

Are Annovis Bio and RenovoRx in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons